Gastroprotection in Low-Dose Aspirin Users for Primary and Secondary Prevention of ACS: Results of a Cost-Effectiveness Analysis Including Compliance
de Groot NL, van Haalen HG, Spiegel BM, Laine L, Lanas A, Focks JJ, Siersema PD, van Oijen MG. Gastroprotection in Low-Dose Aspirin Users for Primary and Secondary Prevention of ACS: Results of a Cost-Effectiveness Analysis Including Compliance. Cardiovascular Drugs And Therapy 2013, 27: 341-357. PMID: 23417566, DOI: 10.1007/s10557-013-6448-y.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAspirinCost-Benefit AnalysisDrug Therapy, CombinationGastrointestinal HemorrhageHealth Care CostsHumansMaleMiddle AgedModels, TheoreticalPatient CompliancePlatelet Aggregation InhibitorsPrimary PreventionProton Pump InhibitorsQuality-Adjusted Life YearsSecondary PreventionConceptsAcute coronary syndromeProton pump inhibitorsUpper GI bleedingSecondary preventionGI bleedingASA monotherapyPPI complianceElevated riskLow-dose ASA usersLow-dose aspirin usersUpper GI side effectsGI side effectsUpper gastrointestinal complicationsCombination of ASABase-case patientProbabilistic sensitivity analysesCost-effectiveness analysisASA usersGastrointestinal complicationsGastroprotective strategiesAspirin usersCoronary syndromePPI useACS eventCase patients